Stratagene Shares Continue to Rise | GenomeWeb
Shares in Stratagene rose 15.9 percent for the trading week ended Tuesday, a week after its shares had gained 17.4 percent. The firm had seen its shares slump to a 52-week low of $3.98 in the month leading up to the turnaround, but investors are clearly showing that they believe the stock was undervalued. The firm’s shares, however, have a long way to go before matching the 52-week high of $11.41.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.